| |
Tuesday, June 17, 2025 | 11am ET / 8am PT We invite you to join industry experts to explore advanced process analytical technologies (PAT), and how they are transforming bioprocessing. Register now. 
|
|
Today’s Big NewsJun 11, 2025 |
|
Monday, June 16, 2025 | 12pm ET / 9am PT Join a candid and informative discussion between precision medicine experts. They will share lessons learned and concrete opportunities to transform clinical trial design, execution and outcomes. Register now. 
|
|
| By Darren Incorvaia The Food and Drug Administration has gone all in on AI since Martin Makary, M.D., took over the agency, most recently demonstrated by the coronation of new generative AI tool Elsa. Now, Makary and Vinay Prasad, M.D., director of the FDA’s Center for Biologics Evaluation and Research, have published an outline of the FDA’s priorities that includes dramatically hastened drug reviews powered by AI document evaluation. |
|
|
|
By Angus Liu Despite an outcry from the biopharmaceutical industry, the U.K. government has kept the rebate rate under a national drug-cost scheme at a higher level compared with previous years. |
By Gabrielle Masson During a Senate hearing, National Institutes of Health Director Jayanta Bhattacharya, M.D., Ph.D., described the past few months as “bumpy," while underscoring Congress’ role in approving a budget and taking full responsibility for the agency’s move away from “politicized science.” |
By Gabrielle Masson Genentech is letting go of 143 employees who are based out of the company's headquarters in South San Francisco. |
|
Wednesday, June 18, 2025 | 12pm ET / 9am PT In this webinar, we will present two new methods for blood preservation that can be easily implemented at any clinical site just after the patient’s blood collection. Register to learn more. 
|
|
By Andrea Park With great power comes great responsibility, and Insulet, accordingly, is using its influence in the diabetes management space to improve the representation of people living with diabetes. |
By Conor Hale Outside Minneapolis, Boston Scientific has put one of its locations up for sale while expanding another nearby, according to The Minnesota Star Tribune. |
By James Waldron Bristol Myers Squibb, via its RayzeBio unit, is handing out $350 million in upfront cash for a phase 1-stage radiopharmaceutical therapy and diagnostic for prostate cancer. |
By Kevin Dunleavy While the race is on to develop antibody-drug conjugate cancer treatments, so too is the competition to manufacture them. Hoping to gain an edge in the rapidly growing market are MilliporeSigma and Simtra BioPharma Solutions, which have forged a five-year partnership. |
By Nick Paul Taylor Novo Nordisk has planted another seed to fuel the blossoming of its obesity business, inking an $812 million deal with Deep Apple Therapeutics to access small molecules against a non-incretin GPCR target. |
By Conor Hale Tandem Diabetes Care will link its AID systems with an upcoming monitor from Abbott that aims to track both blood glucose and ketone levels. |
By Nick Paul Taylor Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and more than $650 million in milestones. |
Fierce podcasts Don’t miss an episode |
| This week on "Podnosis," we explore how employers are rethinking their approach to employee wellbeing—integrating mental, physical and financial health strategies to better reach the people who need them most. |
|
|---|
|
|
|
Supported by 30 years of experience conducting complex Phase I & II clinical trials, QPS Miami supports special populations and diverse indications like NASH, diabetes, obesity and oncology. Learn More. +(2)+(1).png)
|
|
Whitepaper We analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance. Presented by Blue Matter, strategic consultants in the life sciences |
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
